These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21698193)

  • 1. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.
    Biswas S; Dicks MD; Long CA; Remarque EJ; Siani L; Colloca S; Cottingham MG; Holder AA; Gilbert SC; Hill AV; Draper SJ
    PLoS One; 2011; 6(6):e20977. PubMed ID: 21698193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
    Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
    PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
    Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
    PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.
    Kusi KA; Faber BW; Thomas AW; Remarque EJ
    PLoS One; 2009 Dec; 4(12):e8110. PubMed ID: 19956619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.
    Biswas S; Choudhary P; Elias SC; Miura K; Milne KH; de Cassan SC; Collins KA; Halstead FD; Bliss CM; Ewer KJ; Osier FH; Hodgson SH; Duncan CJ; O'Hara GA; Long CA; Hill AV; Draper SJ
    PLoS One; 2014; 9(9):e107903. PubMed ID: 25254500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.
    Biswas S; Spencer AJ; Forbes EK; Gilbert SC; Holder AA; Hill AV; Draper SJ
    J Immunol; 2012 May; 188(10):5041-53. PubMed ID: 22504652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.
    Forbes EK; de Cassan SC; Llewellyn D; Biswas S; Goodman AL; Cottingham MG; Long CA; Pleass RJ; Hill AV; Hill F; Draper SJ
    PLoS One; 2012; 7(9):e44943. PubMed ID: 22984589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
    Draper SJ; Biswas S; Spencer AJ; Remarque EJ; Capone S; Naddeo M; Dicks MD; Faber BW; de Cassan SC; Folgori A; Nicosia A; Gilbert SC; Hill AV
    J Immunol; 2010 Dec; 185(12):7583-95. PubMed ID: 21098232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.
    Goodman AL; Epp C; Moss D; Holder AA; Wilson JM; Gao GP; Long CA; Remarque EJ; Thomas AW; Ammendola V; Colloca S; Dicks MD; Biswas S; Seibel D; van Duivenvoorde LM; Gilbert SC; Hill AV; Draper SJ
    Infect Immun; 2010 Nov; 78(11):4601-12. PubMed ID: 20713623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.
    Hodgson SH; Choudhary P; Elias SC; Milne KH; Rampling TW; Biswas S; Poulton ID; Miura K; Douglas AD; Alanine DG; Illingworth JJ; de Cassan SC; Zhu D; Nicosia A; Long CA; Moyle S; Berrie E; Lawrie AM; Wu Y; Ellis RD; Hill AVS; Draper SJ
    Mol Ther; 2014 Dec; 22(12):2142-2154. PubMed ID: 25156127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria.
    Drew DR; Hodder AN; Wilson DW; Foley M; Mueller I; Siba PM; Dent AE; Cowman AF; Beeson JG
    PLoS One; 2012; 7(12):e51023. PubMed ID: 23227229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.
    Elias SC; Collins KA; Halstead FD; Choudhary P; Bliss CM; Ewer KJ; Sheehy SH; Duncan CJ; Biswas S; Hill AV; Draper SJ
    J Immunol; 2013 Feb; 190(3):1135-47. PubMed ID: 23293353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
    Sheehy SH; Duncan CJ; Elias SC; Collins KA; Ewer KJ; Spencer AJ; Williams AR; Halstead FD; Moretz SE; Miura K; Epp C; Dicks MD; Poulton ID; Lawrie AM; Berrie E; Moyle S; Long CA; Colloca S; Cortese R; Gilbert SC; Nicosia A; Hill AV; Draper SJ
    Mol Ther; 2011 Dec; 19(12):2269-76. PubMed ID: 21862998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
    Ogwang C; Afolabi M; Kimani D; Jagne YJ; Sheehy SH; Bliss CM; Duncan CJ; Collins KA; Garcia Knight MA; Kimani E; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Spencer AJ; Soipei P; Mueller J; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Gantlett K; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Urban BC; Flanagan KL; Ewer KJ; Chilengi R; Hill AV; Bojang K
    PLoS One; 2013; 8(3):e57726. PubMed ID: 23526949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits.
    Remarque EJ; Faber BW; Kocken CH; Thomas AW
    Infect Immun; 2008 Jun; 76(6):2660-70. PubMed ID: 18378635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.
    Terheggen U; Drew DR; Hodder AN; Cross NJ; Mugyenyi CK; Barry AE; Anders RF; Dutta S; Osier FH; Elliott SR; Senn N; Stanisic DI; Marsh K; Siba PM; Mueller I; Richards JS; Beeson JG
    BMC Med; 2014 Oct; 12():183. PubMed ID: 25319190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prime-boost vectored malaria vaccines: progress and prospects.
    Hill AV; Reyes-Sandoval A; O'Hara G; Ewer K; Lawrie A; Goodman A; Nicosia A; Folgori A; Colloca S; Cortese R; Gilbert SC; Draper SJ
    Hum Vaccin; 2010 Jan; 6(1):78-83. PubMed ID: 20061802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.
    Chuang I; Sedegah M; Cicatelli S; Spring M; Polhemus M; Tamminga C; Patterson N; Guerrero M; Bennett JW; McGrath S; Ganeshan H; Belmonte M; Farooq F; Abot E; Banania JG; Huang J; Newcomer R; Rein L; Litilit D; Richie NO; Wood C; Murphy J; Sauerwein R; Hermsen CC; McCoy AJ; Kamau E; Cummings J; Komisar J; Sutamihardja A; Shi M; Epstein JE; Maiolatesi S; Tosh D; Limbach K; Angov E; Bergmann-Leitner E; Bruder JT; Doolan DL; King CR; Carucci D; Dutta S; Soisson L; Diggs C; Hollingdale MR; Ockenhouse CF; Richie TL
    PLoS One; 2013; 8(2):e55571. PubMed ID: 23457473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.
    Kennedy MC; Wang J; Zhang Y; Miles AP; Chitsaz F; Saul A; Long CA; Miller LH; Stowers AW
    Infect Immun; 2002 Dec; 70(12):6948-60. PubMed ID: 12438374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate.
    Giersing B; Miura K; Shimp R; Wang J; Zhou H; Orcutt A; Stowers A; Saul A; Miller LH; Long C; Singh S
    Infect Immun; 2005 Jul; 73(7):3963-70. PubMed ID: 15972483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.